为明确心肌病相关基因变异,研究人员对 40 例土耳其患者行临床外显子组测序(CES),发现MYBPC3变异最多。 心肌病是一种心肌细胞存在缺陷,进而导致心脏功能出现故障的病症。心肌病依据分子和(或)全身改变被分为三大类,且有多个亚型。该疾病的表现与 ...
Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Cohort 1 Data ...
With its first AAV gene therapy program, DiNA-001, in development for the treatment of MYBPC3 hypertrophic cardiomyopathy (HCM), the company and its platform is attracting significant partnering ...
Tenaya Therapeutics, Inc. announced the initiation of dosing in Cohort 2 of its MyPEAK™-1 Phase 1b/2 clinical trial for TN-201, aimed at treating MYBPC3-associated hypertrophic cardiomyopathy (HCM).
Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Cohort 1 Data Accepted for Late-Breaker ...
Business and Program Updates TN-201 - Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy In December 2024, Tenaya reported promising early data from the first cohort of patients in the ...
Pipeline and Near-term Catalysts: Tenaya's lead gene therapy candidates are TN-201, targeting MYBPC3-associated hypertrophic cardiomyopathy or HCM, and TN-401, targeting PKP2-associated ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果